retatrutide 6 mg Triple G Retatrutide Dosage: Week-by-Week Chart 2026

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder

doi: 10.1038/ijo.2013.120 32 SeinoYRasmussenMFNishidaTKakuK

Most adverse events were mild to moderate GI symptoms, consistent with the known class effects of GLP-1based agents. Jastreboff et al., NEJM Additional Observations Some participants experienced a mild increase in resting heart rate similar to other GLP-1 drugs No serious hypoglycemia was observed unless combined with insulin or sulfonylureas A small number reported transient increases in liver enzymes , which normalized No increase in gallbladder events or pancreatitis noted compared to placebo Overall discontinuation rates were low (under 10%) How to Support Tolerance Naturally Stacking Retatrutide (once approved) with lifestyle and supplement support may enhance tolerability: Use Krill Oil to combat inflammation and improve lipid profiles Support gut health with Probiotics to reduce GI discomfort Ensure adequate hydration and electrolytes via INTRA during training or fasted cardio While Retatrutide is still investigational, early trials suggest its no more difficult to tolerate than Semaglutide or Tirzepatide and for many, the results may far outweigh the adjustment phase

How These Results Compare to Other Weight Loss Medicines Retatrutide's 24.2% mean weight loss at 48 weeks exceeds phase 3 data for semaglutide 2.4 mg (~14.9% at 68 weeks) and is comparable to tirzepatide 15 mg (~22.5% at 72 weeks), though no direct head-to-head trials have been conducted

If youre planning to conceive, the FDA recommends stopping semaglutide at least two months before trying to conceive

AUD is a chronic relapsing disorder with a complex neurobiological pathophysiology